found that a new generation of cytarabine (Ara-C) analogs could induce the apoptosis effect in prostate cancer via targeting MK2 and inducing the synergic antitumor effect in p53-deficient prostate cancer cells combining with cabozantinib (39). This evidence concerns the gene TP53 and prostate carcinoma.